MedTrace Logo

AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells

NCT04169022 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2024-02-12

No results posted yet for this study

Summary

AML is one of the most aggressive forms of leukemia, where bone marrow transplantation remains the gold standard treatment, with its known associated toxicities and related mortality. Despite progress in the treatment of leukemic malignancies, especially the emergence of targeted- and immuno-therapies arising from biological genomic knowledge, there remains a need to provide additional strategies for refractory/relapsing (R/R) patients

Aim of this study is to collect biological samples of AML patients in order to validate our Chimeric Antigen Receptor T-cells immunotherapy approach

Conditions

Interventions

OTHER

Sample collection

Sample collection blood and/or bone marrow

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    collaborator OTHER

  • Etablissement Français du Sang

    collaborator OTHER

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-10
Primary Completion
2023-10-02
Completion
2023-10-02

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04169022 on ClinicalTrials.gov